UPB
Upstream Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.80
+1.45%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.76
From 52W high−91.41%
Volume1.60M
Market cap$153.36M
P/E (TTM)—
P/S (TTM)48.6x
Div yield—
Key dataOct 19, 2026
Open
$2.76
From 52W high
−91.41%
Volume
1.60M
Market cap
$153.36M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.7x
P/E (TTM)
—
RSI (14)
17.0
MomentumView details →
1D Return
+1.45%
YTD Return
−89.47%
SummaryUpdated Jun 1, 2026
Upstream Bio, Inc. (NASDAQ:UPB) is a clinical-stage biotechnology company founded in 2021 and headquartered in Waltham, Massachusetts. The company focuses on developing innovative treatments for inflammatory diseases, particularly severe respiratory disorders. Since its incorporation, Upstream Bio has positioned itself as a specialized player in the competitive biotechnology landscape, concentrating its research and development efforts on targeting specific inflammatory pathways that contribute to debilitating respiratory conditions.
Similar companies
Latest newsMore news →
Upstream Bio presented results from the Phase 2 VALIANT trial of verekitug for severe asthma at the ERS Congress 2026 in Barcelona, showing a 56% reduction in AAER versus placebo and improved lung function and FeNO.42d agoUpstream Bio announced pivotal Phase 3 development plans for verekitug in severe asthma and CRSwNP, with trials to start in Q1 2027.49d agoUpstream Bio, Inc. reported a second-quarter net loss of $0.73 per share, narrower than the Zacks Consensus Estimate of a $0.78 loss and slightly improved from a $0.74 loss a year earlier.69d ago